The nucleic acid therapeutics market growth is driven by two primary factors: the increasing prevalence of genetic disorders and the supportive regulatory landscape, including expedited approval pathways.
As genetic diseases continue to rise globally, there is an urgent need for targeted treatments that can address the underlying genetic causes. Nucleic acid-based therapies, such as Antisense Oligonucleotides (ASOs) and RNA-based treatments, offer promising solutions, providing a direct approach to modulating gene expression and treating previously untreatable conditions.
Despite the promising outcomes in treating rare diseases, personalized medicine, and targeting previously undruggable diseases, challenges such as high production costs, delivery mechanisms, and regulatory hurdles persist. However, the market is expected to benefit from ongoing investments in R&D and collaborations, especially following the success of mRNA vaccines during the COVID-19 pandemic. With a strong pipeline of products and improving clinical results, the nucleic acid therapeutics market is set for significant growth in the coming years.
In line with the latest nucleic acid therapeutics market trends, key players operating in the global industry are investing in various technologies such as 3D printing and CAD/CAM in order to design and manufacture dental restorations to unrivaled standards of precision and personalization. Moreover, they are working on developing restorative procedures such as digital orthodontics in order to drive greater productivity and patient outcomes.
Nucleic Acid Therapeutics is a group of drugs that involve the use of nucleic acids, including DNA or RNA, to cure disease. They are designed to alter the genetic material within cells in order to either repair faulty genes, silence aberrant ones, or add new genetic information. Gene therapies, RNA-based treatments such as RNA interference (RNAi), and messenger RNA (mRNA) vaccines are examples.
Nucleic Acid Therapeutics are being investigated for a broad array of diseases, such as genetic diseases, cancer, viral diseases, and autoimmune disorders. Their promise is in their potential to treat diseases at the genetic level, providing more personalized and potent treatments with less toxicity than conventional therapies.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
The prevalence of genetic disorders is on the increase because of inherited genetic mutations as well as de novo mutations (new, sporadic mutations). Disorders like Duchenne muscular dystrophy (DMD), cystic fibrosis (CF), hemophilia, sickle cell anemia, and thalassemia affect millions of people worldwide.
The National Organization for Rare Disorders reports that DMD is one of the most prevalent genetic orphan diseases, occurring in about 1 in 3,500 male births. The condition is caused by mutations of the DMD gene located on the X chromosome, which codes for the manufacture of dystrophin, an essential protein that helps in preserving muscle cell membranes.
Though genetic mutations are the main etiology of these diseases, environmental conditions and lifestyle habits can hasten the onset or enhance vulnerability to genetic illnesses, adding to the increasing incidence.
Improved healthcare infrastructures and diagnostic technologies have made detection easier, even for cases that were not previously diagnosed. Enhanced genetic screening and prenatal diagnosis techniques allow early identification of genetic diseases, raising awareness and diagnosis of these disorders.
Nucleic acid drugs, especially gene therapy, provide a linear method of correcting genetic defects. Such drugs may either introduce healthy copies of genes into the cells of the patient or correct malfunctioning genes, addressing the underlying cause of the disease.
Moreover, RNA-based treatment methods, including mRNA and RNAi, promise to correct genetic mistakes or alter the expression of genes. For instance, mRNA therapeutics can treat genetic diseases by providing corrected mRNA to generate working proteins that the body is unable to produce naturally anymore, with promising cures and propelling the nucleic acid therapeutics market share.
Regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national authorities have a significant role in approving nucleic acid therapeutics. Their role is to ensure that new treatments are safe, effective, and meet strict scientific and ethical standards.
For streamlining the treatment and approval development for life-threatening illnesses such as orphan diseases and genetic disorders, accelerated approval systems have been developed by regulatory authorities. This is especially crucial in the case of nucleic acid therapeutics because several of these diseases lack successful treatments.
Fast Track Designation (FDA): This initiative focuses on accelerating the development and approval of drugs that will treat severe diseases with unmet medical needs. Gene and RNA-based therapeutics, particularly for orphan genetic disorders, tend to be Fast Track designated, resulting in faster access.
Breakthrough Therapy Designation (FDA): The FDA awards this designation to therapies demonstrating significant advancement over the current treatment in clinical trials. It offers advantages such as increased interactions with the FDA, rolling reviews, and greater guidance, significantly shortening time to market.
These accelerated pathways are of immense importance for speeding up the availability of life-saving medicines and are fueling the expansion of the nucleic acid therapeutics market.
Among the therapy type, the Antisense oligonucleotides (ASOs) segment is the leader of the nucleic acid therapeutics market globally in 2024. Antisense oligonucleotides (ASOs) have emerged as a significant player in the nucleic acid therapeutics industry, currently commanding a majority share.
These short, synthetic strands of nucleic acids are designed to bind to specific RNA molecules, effectively modulating gene expression. Their ability to inhibit the production of harmful proteins and promote the degradation of disease-causing RNA has led to their adoption in clinical applications.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
Preeminent biotech and pharmaceutical corporations in North America are the vanguard of innovations in nucleic acid therapy, especially gene and RNA-based therapy. The high prevalence of genetic disorders and cancer has raised the stakes for good treatments, hastening research and clinical trials.
Moreover, effective cooperation between academia and industry has converted innovative research into practical therapies. Regulatory authorities, especially the U.S. Food and Drug Administration (FDA), have helped accelerate drug approvals, providing faster access to new treatments.
The favorable regulatory environment coupled with increased interest in personalized medicine makes North America a world leader in nucleic acid therapeutics, and growth and development are assured in the years ahead.
Companies are actively overcoming delivery method, stability, and cost-effectiveness issues, and this is fueling the clinical uptake of ASOs. Through continued research and strategic partnerships, they are building their pipelines, setting ASOs up to play a central role in the treatment of genetic and chronic diseases in the future.
Novartis AG, Pfizer, Inc., Sanofi, Novo Nordisk A/S, AstraZeneca plc, Alnylam Pharmaceuticals, Inc., Amgen Inc., Sarepta Therapeutics, Inc., Bluebird Bio, Inc., CSL Behring LLC, Ferring Pharmaceuticals Inc., Krystal Biotech, Inc., PTC Therapeutics, Inc., Jazz Pharmaceuticals plc., Astellas Pharma Inc. are some of the leading key players operating in the nucleic acid therapeutics industry.
Each of these players has been profiled in the nucleic acid therapeutics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 8.8 Bn |
| Forecast Value in 2035 | US$ 44.5 Bn |
| CAGR | 14.7% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn |
| Nucleic Acid Therapeutics Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The nucleic acid therapeutics market was valued at US$ 8.8 Bn in 2024.
The nucleic acid therapeutics market is projected to cross US$ 44.5 Bn by the end of 2035.
Increasing prevalence of genetic disorders and regulatory approvals and expedited pathways.
The CAGR is anticipated to be 14.7% from 2025 to 2035.
North America is expected to account for the largest share from 2025 to 2035.
Novartis AG, Pfizer, Inc., Sanofi, Novo Nordisk A/S, AstraZeneca plc, Alnylam Pharmaceuticals, Inc., Amgen Inc., Sarepta Therapeutics, Inc., Bluebird Bio, Inc., CSL Behring LLC, Ferring Pharmaceuticals Inc., Krystal Biotech, Inc., PTC Therapeutics, Inc., Jazz Pharmaceuticals plc., Astellas Pharma Inc. and Others.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nucleic Acid Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecast, 2020 - 2035
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Healthcare Expenditure across Key Regions / Countries
5.2. Technological Advancements in Nucleic Acid Therapeutics Industry
5.3. List of Nucleic Acid Therapeutics Approved by FDA
5.4. Nucleic Acid Therapeutics Pricing Trends
5.5. Nucleic Acid Therapeutics: Clinical Trial Analysis
5.6. Funding and Investments Analysis
5.7. PORTER’s Five Forces Analysis
5.8. Regulatory Landscape across Key Regions / Countries
5.9. Go-to-Market Strategy for New Market Entrants
5.10. Key Purchase Metrics for End-users
5.11. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
5.12. Benchmarking of the Products Offered by the Leading Competitors
5.13. Preclinical Pipeline Analysis for Nucleic Acid Therapeutics
6. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2020 - 2035
6.3.1. Antisense oligonucleotides (ASOs)
6.3.2. Small interfering R(siRNA)
6.3.3. Gene Therapies
6.3.4. Aptamers
6.3.5. Others
6.4. Market Attractiveness Analysis, by Therapy Type
7. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Delivery Method
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Delivery Method, 2020 - 2035
7.3.1. Viral vector-based Delivery Systems
7.3.2. Non-viral Delivery Systems
7.4. Market Attractiveness Analysis, by Delivery Method
8. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020 - 2035
8.3.1. Intravenous
8.3.2. Subcutaneous
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapeutic Area
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Therapeutic Area, 2020 - 2035
9.3.1. Neuromuscular Disorder
9.3.2. Metabolic Disorders
9.3.3. Cardiovascular Disorders
9.3.4. Ophthalmological Disorders
9.3.5. Oncological Disorders
9.3.6. Others
9.4. Market Attractiveness Analysis, by Therapeutic Area
10. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2020 - 2035
10.3.1. Hospitals
10.3.2. Academic and Research Institutes
10.3.3. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020 - 2035
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Nucleic Acid Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2020 - 2035
12.2.1. Antisense oligonucleotides (ASOs)
12.2.2. Small interfering R(siRNA)
12.2.3. Gene Therapies
12.2.4. Aptamers
12.2.5. Others
12.3. Market Value Forecast, by Delivery Method, 2020 - 2035
12.3.1. Viral vector-based Delivery Systems
12.3.2. Non-viral Delivery Systems
12.4. Market Value Forecast, by Route of Administration, 2020 - 2035
12.4.1. Intravenous
12.4.2. Subcutaneous
12.4.3. Others
12.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
12.5.1. Neuromuscular Disorder
12.5.2. Metabolic Disorders
12.5.3. Cardiovascular Disorders
12.5.4. Ophthalmological Disorders
12.5.5. Oncological Disorders
12.5.6. Others
12.6. Market Value Forecast, by End-user, 2020 - 2035
12.6.1. Hospitals
12.6.2. Academic and Research Institutes
12.6.3. Others
12.7. Market Value Forecast, by Country, 2020 - 2035
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Therapy Type
12.8.2. By Delivery Method
12.8.3. By Route of Administration
12.8.4. By Therapeutic Area
12.8.5. By End-user
12.8.6. By Country
13. Europe Nucleic Acid Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2020 - 2035
13.2.1. Antisense oligonucleotides (ASOs)
13.2.2. Small interfering R(siRNA)
13.2.3. Gene Therapies
13.2.4. Aptamers
13.2.5. Others
13.3. Market Value Forecast, by Delivery Method, 2020 - 2035
13.3.1. Viral vector-based Delivery Systems
13.3.2. Non-viral Delivery Systems
13.4. Market Value Forecast, by Route of Administration, 2020 - 2035
13.4.1. Intravenous
13.4.2. Subcutaneous
13.4.3. Others
13.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
13.5.1. Neuromuscular Disorder
13.5.2. Metabolic Disorders
13.5.3. Cardiovascular Disorders
13.5.4. Ophthalmological Disorders
13.5.5. Oncological Disorders
13.5.6. Others
13.6. Market Value Forecast, by End-user, 2020 - 2035
13.6.1. Hospitals
13.6.2. Academic and Research Institutes
13.6.3. Others
13.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
13.7.1. Germany
13.7.2. UK
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Therapy Type
13.8.2. By Delivery Method
13.8.3. By Route of Administration
13.8.4. By Therapeutic Area
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2020 - 2035
14.2.1. Antisense oligonucleotides (ASOs)
14.2.2. Small interfering R(siRNA)
14.2.3. Gene Therapies
14.2.4. Aptamers
14.2.5. Others
14.3. Market Value Forecast, by Delivery Method, 2020 - 2035
14.3.1. Viral vector-based Delivery Systems
14.3.2. Non-viral Delivery Systems
14.4. Market Value Forecast, by Route of Administration, 2020 - 2035
14.4.1. Intravenous
14.4.2. Subcutaneous
14.4.3. Others
14.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
14.5.1. Neuromuscular Disorder
14.5.2. Metabolic Disorders
14.5.3. Cardiovascular Disorders
14.5.4. Ophthalmological Disorders
14.5.5. Oncological Disorders
14.5.6. Others
14.6. Market Value Forecast, by End-user, 2020 - 2035
14.6.1. Hospitals
14.6.2. Academic and Research Institutes
14.6.3. Others
14.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Therapy Type
14.8.2. By Delivery Method
14.8.3. By Route of Administration
14.8.4. By Therapeutic Area
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapy Type, 2020 - 2035
15.2.1. Antisense oligonucleotides (ASOs)
15.2.2. Small interfering R(siRNA)
15.2.3. Gene Therapies
15.2.4. Aptamers
15.2.5. Others
15.3. Market Value Forecast, by Delivery Method, 2020 - 2035
15.3.1. Viral vector-based Delivery Systems
15.3.2. Non-viral Delivery Systems
15.4. Market Value Forecast, by Route of Administration, 2020 - 2035
15.4.1. Intravenous
15.4.2. Subcutaneous
15.4.3. Others
15.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
15.5.1. Neuromuscular Disorder
15.5.2. Metabolic Disorders
15.5.3. Cardiovascular Disorders
15.5.4. Ophthalmological Disorders
15.5.5. Oncological Disorders
15.5.6. Others
15.6. Market Value Forecast, by End-user, 2020 - 2035
15.6.1. Hospitals
15.6.2. Academic and Research Institutes
15.6.3. Others
15.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Therapy Type
15.8.2. By Delivery Method
15.8.3. By Route of Administration
15.8.4. By Therapeutic Area
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Therapy Type, 2020 - 2035
16.2.1. Antisense oligonucleotides (ASOs)
16.2.2. Small interfering R(siRNA)
16.2.3. Gene Therapies
16.2.4. Aptamers
16.2.5. Others
16.3. Market Value Forecast, by Delivery Method, 2020 - 2035
16.3.1. Viral vector-based Delivery Systems
16.3.2. Non-viral Delivery Systems
16.4. Market Value Forecast, by Route of Administration, 2020 - 2035
16.4.1. Intravenous
16.4.2. Subcutaneous
16.4.3. Others
16.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
16.5.1. Neuromuscular Disorder
16.5.2. Metabolic Disorders
16.5.3. Cardiovascular Disorders
16.5.4. Ophthalmological Disorders
16.5.5. Oncological Disorders
16.5.6. Others
16.6. Market Value Forecast, by End-user, 2020 - 2035
16.6.1. Hospitals
16.6.2. Academic and Research Institutes
16.6.3. Others
16.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Therapy Type
16.8.2. By Delivery Method
16.8.3. By Route of Administration
16.8.4. By Therapeutic Area
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis, by Company (2024)
17.3. Company Profiles
17.3.1. Novartis AG
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Pfizer, Inc.
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Sanofi
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Novo Nordisk A/S
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. AstraZeneca plc
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Alnylam Pharmaceuticals, Inc.
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. Amgen Inc
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Sarepta Therapeutics, Inc.
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Bluebird Bio, Inc
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. CSL Behring LLC
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
17.3.11. Ferring Pharmaceuticals Inc.
17.3.11.1. Company Overview
17.3.11.2. Financial Overview
17.3.11.3. Product Portfolio
17.3.11.4. Business Strategies
17.3.11.5. Recent Developments
17.3.12. Krystal Biotech, Inc.
17.3.12.1. Company Overview
17.3.12.2. Financial Overview
17.3.12.3. Product Portfolio
17.3.12.4. Business Strategies
17.3.12.5. Recent Developments
17.3.13. PTC Therapeutics, Inc.
17.3.13.1. Company Overview
17.3.13.2. Financial Overview
17.3.13.3. Product Portfolio
17.3.13.4. Business Strategies
17.3.13.5. Recent Developments
17.3.14. Jazz Pharmaceuticals plc
17.3.14.1. Company Overview
17.3.14.2. Financial Overview
17.3.14.3. Product Portfolio
17.3.14.4. Business Strategies
17.3.14.5. Recent Developments
17.3.15. Astellas Pharma Inc.
17.3.15.1. Company Overview
17.3.15.2. Financial Overview
17.3.15.3. Product Portfolio
17.3.15.4. Business Strategies
17.3.15.5. Recent Developments
List of Tables
Table 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
Table 02: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
Table 03: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
Table 04: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
Table 05: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
Table 06: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Region, 2020 - 2035
Table 07: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country, 2020-2035
Table 08: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
Table 09: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
Table 10: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
Table 11: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
Table 12: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
Table 13: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
Table 14: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
Table 15: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
Table 16: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
Table 17: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
Table 18: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
Table 19: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
Table 20: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
Table 21: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
Table 22: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
Table 23: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
Table 24: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
Table 25: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
Table 26: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
Table 27: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
Table 28: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
Table 29: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
Table 30: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
Table 31: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
Table 32: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
Table 33: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
Table 34: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
Table 35: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
Table 36: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
List of Figures
Figure 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
Figure 02: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 03: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
Figure 04: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Antisense oligonucleotides (ASOs), 2020 - 2035
Figure 05: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Small interfering RNA (siRNA), 2020 - 2035
Figure 06: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Gene Therapies, 2020 - 2035
Figure 07: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Aptamers, 2020 - 2035
Figure 08: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
Figure 09: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
Figure 10: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
Figure 11: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Viral vector-based Delivery Systems, 2020 - 2035
Figure 12: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Non-viral Delivery Systems, 2020 - 2035
Figure 13: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 14: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
Figure 15: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Intravenous, 2020 - 2035
Figure 16: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Subcutaneous, 2020 - 2035
Figure 17: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
Figure 18: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 19: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
Figure 20: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Neuromuscular Disorder, 2020 - 2035
Figure 21: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Metabolic Disorders, 2020 - 2035
Figure 22: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Cardiovascular Disorders, 2020 - 2035
Figure 23: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Ophthalmological Disorders, 2020 - 2035
Figure 24: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Oncological Disorders, 2020 - 2035
Figure 25: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
Figure 26: Global Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 27: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
Figure 28: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Hospitals, 2020 - 2035
Figure 29: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Academic and Research Institutes, 2020 - 2035
Figure 30: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
Figure 31: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Region, 2024 and 2035
Figure 32: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Region, 2025 - 2035
Figure 33: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
Figure 34: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
Figure 35: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country, 2025 - 2035
Figure 36: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 37: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
Figure 38: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
Figure 39: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
Figure 40: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 41: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
Figure 42: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 43: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
Figure 44: North America Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 45: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
Figure 46: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
Figure 47: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 48: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
Figure 49: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 50: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
Figure 51: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
Figure 52: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
Figure 53: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 54: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
Figure 55: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 56: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
Figure 57: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 58: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
Figure 59: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
Figure 60: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 61: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025 - 2035
Figure 62: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 63: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
Figure 64: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
Figure 65: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
Figure 66: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 67: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
Figure 68: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 69: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
Figure 70: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 71: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
Figure 72: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
Figure 73: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 74: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
Figure 75: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 76: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
Figure 77: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
Figure 78: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
Figure 79: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 80: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
Figure 81: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 82: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
Figure 83: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 84: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
Figure 85: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
Figure 86: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 87: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
Figure 88: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
Figure 89: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
Figure 90: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
Figure 91: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
Figure 92: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 93: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
Figure 94: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 95: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
Figure 96: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 97: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Nucleic Acid Therapeutics Market
